Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a U.S.-based medical device company focused on developing nitric oxide technologies for hospital, clinical, research, and mobile delivery applications. The company was formed to design, manufacture, and market nitric oxide generating formulations and delivery systems for use in medical procedures and related laboratory settings.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCompound-based technologies designed to generate nitric oxide for medical and research use.
Bedside nitric oxide delivery systems intended for hospital use in clinical care settings.
Portable or clinic-based nitric oxide delivery units for medical clinics and rehabilitation centers.
Rechargeable mobile devices designed to deliver nitric oxide gas outside fixed hospital settings.
Nitric oxide systems used for non-clinical laboratory and research applications.
Asiakkaat
Nu-Med Plus targets hospitals, health systems, clinics, rehabilitation centers, and medical professionals that use nitric oxide in patient care. It also addresses research and laboratory users that need nitric oxide systems for non-clinical applications. The company’s products are aimed at buyers seeking specialized delivery technologies for defined medical procedures and use cases.
Buy bedside nitric oxide delivery systems for inpatient clinical use and procedure support.
Buy clinical nitric oxide units for outpatient or specialty care settings.
Buy nitric oxide systems for non-clinical laboratory and research applications.
Influence adoption by specifying devices that address a defined procedural need.
Potential buyers of early non-medical or lab-use units outside the U.S. approval pathway.
Strategia
The company’s strategy is to develop nitric oxide technologies that address specific medical needs and then commercialize them across hospital, clinic, research, and mobile-use settings. It also appears to pursue early non-clinical or laboratory sales as a bridge toward broader medical adoption, while keeping the core focus on FDA-regulated human-use devices.
Product development is the basis for future commercialization and market entry.
Human medical use in the U.S. and abroad requires FDA and foreign agency clearance.
Earlier non-clinical sales could create initial market presence before medical approval.
Maantiede
Nu-Med Plus is headquartered in Port Jefferson, New York and was incorporated in Utah. Its products are intended for use in the United States and in international markets, but human medical sales depend on regulatory approval in each jurisdiction. Geography matters because the company’s addressable market is shaped by FDA and foreign agency requirements for nitric oxide devices.
Riskit
Nu-Med Plus faces development, regulatory, and financing risk because its products require substantial testing and approval before human medical sales can begin. As an early-stage medical device company with no revenue disclosed, it is also exposed to customer adoption risk, supplier dependence, and the need for additional capital to continue operations.
- Financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has no revenue disclosed and depends on capital infusions to fund development and operations.
Kohdistuu: Product development and corporate continuity
- Regulatory approval riskVaikutus: Kriittinen
Human medical use of nitric oxide devices requires FDA and foreign agency approval before sales.
Kohdistuu: U.S. and international medical device commercialization
- Development and commercialization riskVaikutus: KorkeaTodennäköisyys: Korkea
Devices may not reach market acceptance or may take longer and cost more than expected to develop.
Kohdistuu: Nitric oxide delivery systems and research products
- Customer adoption riskVaikutus: Keskitaso
Hospitals and clinicians may be slow to adopt a new nitric oxide platform versus existing alternatives.
Kohdistuu - Credit risk on receivablesVaikutus: Matala
If sales begin, the company may need allowances for doubtful accounts when customers delay payment.
Kohdistuu: Trade receivables
Kirjanpito
Harkinnanvaraiset erätThe company states it currently has no revenue, so future recognition will depend on contract terms and delivery timing.
Vaikutus: Will affect reported sales timing once commercialization starts
Management must estimate collectability if receivables arise from future customers.
Vaikutus: Could affect net revenue and operating results
Deferred tax assets are only recognized when realization is more likely than not.
Vaikutus: Could affect balance sheet assets and tax expense
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Nuo Therapeutics, Inc.
AURX · Surgical & Medical Instruments & Apparatus
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Nuwellis, Inc.
NUWE · Electromedical & Electrotherapeutic Apparatus
Beyond Air, Inc.
XAIR · Surgical & Medical Instruments & Apparatus
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Päivitetty: 24.9.2026